TLDR

  • Rocket Lab (RKLB) gained 10.2% on Tuesday, reaching $78.59 in its third consecutive session of advances.
  • The surge followed the company’s disclosure of two Electron rocket missions scheduled within days of each other.
  • The session saw 28.4 million shares traded — approximately 33% higher than typical daily activity.
  • Bank of America maintains a $120 price target on RKLB, significantly exceeding the analyst consensus of $75.92.
  • Company insiders have divested approximately $139 million in shares during the previous three months, while institutional ownership remains at roughly 71.8%.

Rocket Lab shares advanced 10.2% during Tuesday’s trading session, finishing at $78.59. The increase coincided with the company’s revelation of two scheduled Electron rocket deployments.


RKLB Stock Card
Rocket Lab USA, Inc., RKLB

The previous session had ended at $71.31, making Tuesday the third consecutive day of upward momentum for RKLB.

Trading activity reflected heightened investor interest: 28.4 million shares exchanged hands throughout the session — a figure 33% higher than the typical daily volume of approximately 21.3 million.

The aerospace company revealed plans for its 84th Electron mission, designated “Eight Days A Week,” scheduled for launch no later than Friday, March 20. This mission will deliver a synthetic aperture radar satellite to low Earth orbit (LEO) for integration into Synspective’s StriX constellation.

A subsequent launch, the 85th Electron mission titled “Daughter of the Stars,” has been scheduled for no later than Tuesday, March 24. This mission represents Rocket Lab’s inaugural deployment for the European Space Agency (ESA), carrying two Pathfinder A satellites designed to validate a novel LEO satellite navigation system.

“Integration and encapsulation is now complete, with ESA’s 2x satellites secured to Electron inside its nose cone and ready for launch,” Rocket Lab said in a post on X.

Both missions will depart from Launch Complex 1 located at Mahia Peninsula in New Zealand.

Analyst Targets and Ratings

Wall Street maintains a generally favorable outlook on RKLB, though opinions vary. The prevailing consensus rating stands at “Moderate Buy,” with an average price objective of $75.92 — marginally below Tuesday’s closing price.

Bank of America emerges as the most optimistic analyst, elevating its price target from $60 to $120 in January while assigning a “Buy” rating to the stock.

The complete analyst spectrum comprises one Strong Buy, seven Buys, seven Holds, and one Sell. Zacks adjusted the stock from Strong Buy to Hold during February, while TD Cowen continues to uphold its Buy rating.

The company shows a market capitalization of $41.98 billion, a debt-to-equity ratio of 0.10, a quick ratio of 3.61, and a current ratio of 4.08. The 200-day moving average rests at $63.25.

Insider Activity

Some stakeholders have chosen to reduce positions at current valuations. Throughout the past three months, company insiders have liquidated approximately 1.85 million shares valued at roughly $139 million in aggregate.

SVP Arjun Kampani divested 23,711 shares on March 4 at an average price of $71.95, decreasing his holdings by 5.62%. Insider Frank Klein similarly sold 36,768 shares on the same date at the identical price, reducing his position by 3.27%.

Despite these transactions, corporate insiders continue to control 11.9% of the company. Institutional investors and hedge funds maintain ownership of approximately 71.8%, with multiple smaller funds establishing new positions during the fourth quarter of the previous year.

RKLB displays a trailing P/E of -212.40 and a beta of 2.20, indicating its elevated volatility characteristics. The 50-day moving average registers at $77.33.